You can see the complete list of Zacks #1 Rank stocks here.ĪdaptHealth has a projected long-term earnings growth rate of 720%. VIVO, each sporting a Zacks Rank #1 (Strong Buy). AHCO, Quidel Corporation QDEL and Meridian Bioscience Inc. Some better-ranked stocks from the broader medical space include AdaptHeath Corp. Zacks Rank and Key PicksĬurrently, Insulet carries a Zacks Rank #4 (Sell). Shares of the company have gained 49% in a year’s time compared with the industry’s growth of 3.7%. Per company guidance, total Omnipod revenues in fourth-quarter 2020 are expected to grow 10-14%. Notably, Omnipod DASH drove approximately 65% of U.S. In the third quarter, Insulet’s Omnipod business growth was 18% year over year. Increasing cases of diabetes across the globe will accelerate the adoption of tubeless insulin pump systems for better care and management of disease and is anticipated to witness significant growth in the upcoming years. Per a report by Global Market Insights, the global tubeless insulin pump market size was valued at $549.6 million in 2018 and is expected to reach $2.4 billion by 2025, at a CAGR of 24.0%. Per feedback received from Rebecca Redmond, among the first Omnipod DASH users in Canada, the system supports better and more proactive diabetes management as it acts as a tool to rotate Pod sites, making insulin absorption more effective. Moreover, the Pod comes with a waterproof IP28 rating for up to 7.6 metres for an hour. The Omnipod DASH System offers an insightful interface that allows users to wirelessly control the amount and flow rate of insulin supplies to the body through Pod. Per management, the launch of this innovative and convenient insulin delivery system in Canada, which provides touchscreen Personal Diabetes Manager (PDM) combined with existing benefits of Pod therapy, will bring more flexibility and options to simplify diabetes management for Canadian users.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |